Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with Radiotherapy for Inflammatory Breast Cancer
NCT03598257Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of olaparib in inflammatory breast cancer (IBC), sponsored by National Cancer Institute. Started Jan 2019; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03598257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598257.